Does the CORT Form 4 indicate any share sales or dispositions by William Guyer?

The Form 4 shows only acquisition-type transactions for Guyer, with no reported sales. Both entries use transaction code A, indicating grants or other acquisitions of common stock tied to the 2024 Incentive Award Plan and associated purchase plan, rather than dispositions.

CORT CDO awarded and buys 1,754 company shares

Corcept Therapeutics Chief Development Officer William Guyer reported stock-based compensation and share purchases in company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics Chief Development Officer William Guyer reported stock-based compensation and share purchases in company stock. On June 1, 2026, he acquired 877 shares of common stock as a grant at $0.00 per share and an additional 877 shares at $70.44 per share under a purchase plan established within the 2024 Incentive Award Plan. Footnotes show these include shares underlying unvested restricted stock awards, which vest in full one year after their grant dates if service and ownership conditions are met.

Insider Trade Summary

Grant/Award: 1,754 shares

Grant/Award 2 txns

Insider Guyer William

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	877	$70.44	$62K
Grant/Award	Common Stock	877	$0.00	$0.00

Holdings After Transaction: Common Stock — 3,985 shares (Direct)

Footnotes (4)

F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.
F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Key Figures

Grant shares: 877 shares Purchase plan shares: 877 shares at $70.44 Post-transaction holding (line 1): 3,985 shares +2 more

5 metrics

Grant shares 877 shares Common Stock grant at $0.00 per share on June 1, 2026

Purchase plan shares 877 shares at $70.44 Common Stock purchased under Purchase Plan on June 1, 2026

Post-transaction holding (line 1) 3,985 shares Total common shares following the grant transaction

Post-transaction holding (line 2) 3,108 shares Total common shares following the purchase plan transaction

Unvested RSA components 224 and 498 shares Restricted stock awards from Dec 1, 2025 and Mar 2, 2026

Key Terms

Purchase Plan, 2024 Incentive Award Plan, restricted stock awards, beneficial owner, +1 more

5 terms

Purchase Plan financial

"purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan")"

2024 Incentive Award Plan financial

"purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan"

restricted stock awards financial

"Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

beneficial owner financial

"vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

transaction code A financial

"transaction_code": "A" ... transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CORT executive William Guyer report on June 1, 2026?

William Guyer reported acquiring Corcept Therapeutics common stock through compensation-related awards and a purchase plan. On June 1, 2026, he received 877 shares at $0.00 per share and bought 877 shares at $70.44 per share under the company’s 2024 Incentive Award Plan.

Was the CORT Form 4 transaction a market buy or compensation grant?

The Form 4 for Corcept Therapeutics shows compensation-related acquisitions, not open-market trading. Guyer received 877 common shares as a stock grant at $0.00 and 877 shares through a purchase plan at $70.44, all under the 2024 Incentive Award Plan framework.

What price did William Guyer pay for Corcept Therapeutics (CORT) shares in the purchase plan?

Under the purchase plan, Guyer acquired 877 Corcept Therapeutics common shares at $70.44 per share. Footnotes state the price was based on the closing price on the day of purchase, consistent with the terms of the company’s Purchase Plan within the 2024 Incentive Award Plan.

How do the restricted stock awards for CORT’s William Guyer vest?

Guyer’s restricted stock awards vest 100% on the one-year anniversary of each grant date. Footnotes note 224 shares from December 1, 2025 and 498 shares from March 2, 2026, plus awards under the Purchase Plan, all subject to continued service and ownership conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/03/2026 - 07:24 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/01/2026		A		877⁽¹⁾	A	$70.44⁽²⁾	3,108⁽³⁾	D
Common Stock	06/01/2026		A		877⁽⁴⁾	A	$0.00	3,985⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 1, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025 and 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR